At a glance
- Originator Merck & Co
- Class Antineoplastics; Small molecules; Tricarboxylic acids
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Cancer in Spain (unspecified route)
- 12 Feb 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 14 Feb 2000 No-Development-Reported for Cancer in USA (unspecified route)